Feature | June 01, 2015

Peer-Reviewed Publication Shows Larger Capacity IABP Have Greater Hemodynamic Effect on Patients

Retrospective study examines 50 cc IABPs versus 40 cc IABPs in real-world practice

IABP, peer review, Maquet, Journal of Invasive Cardiology

June 1, 2015 — Maquet Getinge Group announced the publication of a manuscript describing the exploration of the hemodynamic effects of the newer, larger-capacity 50 cc intra-aortic balloon pumps (IABPs) versus 40 cc IABPs in real-world clinical practice. The paper, titled "Hemodynamic Effects of Standard Versus Larger-Capacity Intraaortic Balloon Counterpulsation Pumps," appears in the April 2015 volume of The Journal of Invasive Cardiology.

The study, led by Navin K. Kapur, M.D., assistant director of the Interventional Cardiology Center at Tufts Medical Center; investigator at Tufts Molecular Cardiology Research Institute; and assistant professor at Tufts University School of Medicine, was a retrospective examination of demographic, hemodynamic and laboratory data in 26 consecutive subjects treated with a 50 cc IABP. These patients were compared with 26 patients receiving a 40 cc IABP between 2012 and 2013. IABP tracings were analyzed within 24 hours of implantation in all patients. Pulmonary artery catheter data were available before and after IABP implantation in 20 subjects.

The study found that the larger-capacity 50 cc IABPs provides greater diastolic augmentation and systolic unloading compared with the 40 cc IABP. In the analysis, recipients of the 50 cc IABP were observed to achieve a greater reduction in cardiac filling pressures and increased cardiac output compared with the 40 cc group. It was also observed that a greater number of patients achieved a reduction in systolic pressure in the 50 cc IABP group compared with the 40 cc IABP group — the magnitude of systolic unloading correlates directly with the magnitude of diastolic augmentation and inversely with pulmonary artery occlusion pressure. Taken together, these observations suggest that the 50 cc IABP may achieve a greater hemodynamic effect compared with the standard 40 cc IABP.

"The intra-aortic balloon pump remains the most widely used form of mechanical hemodynamic support for cardiac patients because of their clinical efficacy and safety profile across a broad range of patient care scenarios," said Marc Cohen, chief of the Division of Cardiology at Newark Beth Israel Medical Center, Newark, New Jersey, and professor of medicine at Rutgers-New Jersey Medical School. "Given IABPs' continuing role in the management of high-risk patients with and without cardiogenic shock, new research into the newer 50 cc balloon is key to better understanding the role of IABPs in the modern era of acute cardiovascular care. The 50 cc IABP recipients demonstrated higher augmented diastolic blood pressure and greater systolic unloading compared to 40 cc IAB patients which is encouraging and warrants more research into whether this larger capacity balloon offers meaningful morbidity and mortality benefits."

For more information: www.invasivecardiology.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init